Maschio Michael, Kohli Michele A, Ashraf Mansoor, Drummond Michael F, Weinstein Milton C, Mould-Quevedo Joaquin F
Quadrant Health Economics Inc., 92 Cottonwood Crescent, Cambridge, ON N1T 2J1, Canada.
Seqirus UK, Point, Level 3, 8AA, 29 Market St., Maidenhead SL6 8AD, UK.
Vaccines (Basel). 2022 Apr 13;10(4):599. doi: 10.3390/vaccines10040599.
: In the United Kingdom (UK), a cell-based quadrivalent influenza vaccine (QIVc) and a recombinant vaccine (QIVr) are recommended for eligible adults under 65 years. The objective of this analysis was to determine the potential cost-effectiveness of QIVc compared to QIVr for this age group using a range of assumptions about relative vaccine effectiveness (rVE). A dynamic transmission model, calibrated to match infection data from the UK, was used to estimate the clinical and economic impact of vaccination across 10 influenza seasons. The list price was £12.50 for QIVc and £22.00 for QIVr. The base case effectiveness of QIVc was 63.9%. As there are no data comparing the vaccines in the 18 to 64-year-old age group, rVE was varied. For the base case, the rVE of QIVr compared with QIVc must be at least 25% in order for the cost per quality-adjusted life-year gained to be £20,000 or lower. Sensitivity analysis demonstrated that the rVE required for QIVr to be cost-effective was most dependent on the absolute effectiveness of QIVc. At list prices, our analysis predicts that the rVE for QIVr must be at least 25% compared to QIVc in order to be considered cost-effective.
在英国，对于65岁以下符合条件的成年人，推荐使用基于细胞的四价流感疫苗（QIVc）和重组疫苗（QIVr）。本分析的目的是使用一系列关于相对疫苗效力（rVE）的假设，确定QIVc与QIVr相比对于该年龄组的潜在成本效益。使用一个经过校准以匹配英国感染数据的动态传播模型，来估计10个流感季节接种疫苗的临床和经济影响。QIVc的标价为12.50英镑，QIVr的标价为22.00英镑。QIVc的基础效力为63.9%。由于没有18至64岁年龄组中比较这两种疫苗的数据，rVE有所不同。对于基础情况，为了使每获得一个质量调整生命年的成本为20,000英镑或更低，与QIVc相比，QIVr的rVE必须至少为25%。敏感性分析表明，QIVr具有成本效益所需的rVE最依赖于QIVc的绝对效力。按标价计算，我们的分析预测，与QIVc相比，QIVr的rVE必须至少为25%才能被认为具有成本效益。
